Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?
Table 2
Results of simple regression models among the 71 patients with early RA with the concentration of Lp-PLA2 at T0 as the dependent variable.
Lp-PLA2 at T0
β
95% CI
value
IMT T0 (n = 70)
9.7/mm
2.1; 17.2
0.013†
IMT T5 (n = 70)
8.8/mm
1.4; 16.2
0.02†
FMD T0 (n = 70)
−2.4/%
−4.5; −0.4
0.02
FMD T5 (n = 70)
−2.5/%
−4.6; −0.5
0.02
Non-HDL-cholesterol T0 (n = 54)
16.9/mmolL−1
5.8; 28.0
0.004
HDL T0 (n = 55)
−22.6/mmolL−1
−42.0; −3.1
0.02
Diastolic blood pressure T0 (n = 66)
1.3/mmHg
0.1; 2.5
0.04
Ever smoking (n = 70)
0.8/year
0.08; 1.4
0.03
SCORE T0 (n = 53)
11.4/unit
3.3; 19.5
0.007
Reynolds Risk Score T0 (n = 38)
5.2/unit
1.5; 8.8
0.007
Larsen score T0 (n = 50)
2.9/unit
0.013; 5.90
0.05
Still significant after adjustment for sex and age. RA: rheumatoid arthritis; Lp-PLA2: lipoprotein-associated phospholipase A2; IMT: intima media thickness; FMD: flow mediated dilation; HDL: high-density lipoproteins.
